Comparison of Extrapulmonary Small Cell Carcinoma and Small Cell Lung Carcinoma: A Single-Center Study
Received Date : 10 Apr 2023
Accepted Date : 28 Aug 2023
Available Online : 02 Oct 2023
Doi: 10.37047/jos.2023-97197 - Article's Language: EN
Journal of Oncological Sciences. 2023;9(3):134-41.
This is an open access article under the CC BY-NC-ND license
Objective: This study aimed to compare the clinical features, prognosis, and survival rates of patients with small cell carcinoma of the lung or extrapulmonary origin to get a new perspective for customized treatment strategies for both diseases. Material and Methods: We evaluated 254 patients with either small cell lung carcinoma (SCLC) or extrapulmonary small cell carcinoma (EPSCC) who were diagnosed and treated at Trakya University Hospital, Department of Medical Oncology from 2010 to 2020. We also compared these groups regarding their disease control rate, disease-free survival (DFS) in the limited disease (LD) stage, radiological progression-free survival (PFS), and overall survival (OS). Results: The SCLC group showed a male predominance, which was statistically significant. There was a statistically significant difference was observed concerning bone and brain metastases in the SCLC group. The median DFS was 16.7 and 9.4 months in the EPSCC and the SCLC groups with LD, respectively. Additionally, PFS and OS were similar between LD and extensive disease (ED) stage patients, respectively. Several factors like the presence of liver metastasis at the time of diagnosis, patients >60 years, poor performance status, and high lactate dehydrogenase (LDH) levels were associated with poor OS in ED patients. Conclusion: Although a significant difference was observed in DFS between both groups in LD patients, there was no significant difference between OS and PFS in LD and ED patients of SCLC and EPSCC groups, respectively. Moreover, the presence of liver metastasis and high LDH levels were a few factors that negatively affected the OS of patients.
  1. Aly R, Gupta S, Potdar R. The role of immune checkpoint inhibitors in the treatment of extensive-stage extrapulmonary small cell carcinoma. Cureus. 2020;12(6):e8862. [Crossref]  [PubMed]  [PMC] 
  2. Berniker AV, Abdulrahman AA, Teytelboym OM, Galindo LM, Mackey JE. Extrapulmonary small cell carcinoma: imaging features with radiologic-pathologic correlation. Radiographics. 2015;35(1):152-163. [Crossref]  [PubMed] 
  3. Frazier SR, Kaplan PA, Loy TS. The pathology of extrapulmonary small cell carcinoma. Semin Oncol. 2007;34(1):30-38. [Crossref]  [PubMed] 
  4. Haider K, Shahid RK, Finch D, et al. Extrapulmonary small cell cancer: a Canadian province's experience. Cancer. 2006;107(9):2262-2269. [Crossref]  [PubMed] 
  5. Barnes H, See K, Barnett S, Manser R. Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst Rev. 2017;4(4):CD011917. [Crossref]  [PubMed]  [PMC] 
  6. Grossman RA, Pedroso FE, Byrne MM, Koniaris LG, Misra S. Does surgery or radiation therapy impact survival for patients with extrapulmonary small cell cancers? J Surg Oncol. 2011;104(6):604-612. [Crossref]  [PubMed] 
  7. Xu JL, Guo Y. Clinical characteristics and survival of extrapulmonary small cell carcinoma in 11 different primary tumor sites in the United States, 1975-2016. Curr Med Res Opin. 2021;37(1):71-81. [Crossref]  [PubMed] 
  8. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-4544. [Crossref]  [PubMed] 
  9. Dakhil CS, Wick JA, Kumar AK, Satyan MT, Neupane P. Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature. Med Oncol. 2014;31(10):187. [Crossref]  [PubMed]  [PMC] 
  10. Terashima T, Morizane C, Hiraoka N, et al. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology. 2012;96(4):324-332. [Crossref]  [PubMed] 
  11. Cicin I, Karagol H, Uzunoglu S, et al. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study. Cancer. 2007;110(5):1068-1076. [Crossref]  [PubMed] 
  12. Mandish SF, Gaskins JT, Yusuf MB, Little BP, Dunlap NE. Extrapulmonary small cell carcinoma: prognostic factors, patterns of care, and overall survival. Eur J Surg Oncol. 2020;46(9):1596-1604. [Crossref]  [PubMed] 
  13. Lee SS, Lee JL, Ryu MH, et al. Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol. 2007;46(6):846-851. [Crossref]  [PubMed] 
  14. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476-484. [Crossref]  [PubMed] 
  15. Slotman B, Faivre-Finn C, Kramer G, et al; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664-672. [Crossref]  [PubMed] 
  16. de M Rêgo JF, de Medeiros RSS, Braghiroli MI, et al. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. Ecancermedicalscience. 2017;11:767. [Crossref]  [PubMed]  [PMC] 
  17. Gaspar LE, McNamara EJ, Gay EG, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer. 2012;13(2):115-122. [Crossref]  [PubMed] 
  18. Wang H, Shan D, Dong Y, Yang X, Zhang L, Yu Z. Correlation analysis of serum cystatin C, uric acid and lactate dehydrogenase levels before chemotherapy on the prognosis of small-cell lung cancer. Oncol Lett. 2021;21(1):73. [Crossref]  [PubMed]  [PMC]